Yeah, I am going to speak up on this and say that I am
Yeah, I am going to speak up on this and say that I am going to agree with Sox on this one. I am not saying I am arguing that the shorting issue is not happening, and I am not saying that it is all Aspire dumping shares. (Quite frankly it is probably like everything else in life, many different factors creating a sea of grey rather than the black and white world which we all like to think it is.)
That said the fact that the discussion here is almost always focused on manipulation, shorting, and the ways in which IPIX's SP is getting screwed is only scaring people away. IPIX already has an inherent stigma for no other reason than it is a thinly traded OTC stock with no revenue. That in and of itself keeps many investors from diving in. I know we cant change that, but we can change the fact that we should be beating the positives of the science and the highlights of the company into the ground day in and day out, rather than the negatives of the markets. I remember when ihub and this board were mostly positive posts (years ago), with discussions on the ways in which IPIX's drugs were going to change things for the better and talk about all the different pathways the company had to choose from to become greater in the future. Those kind of talks made an investor like me excited to be part of this ride.
So for all parties involved in this debate; we have to change the narrative on this board back to one of a positive outlook. Yeah we are still going to have to fight the trolls that show up here to spread their FUD and mental manipulation, but we should at least stop with the same constant arguments post after post. We are doing nobody a favor here.
My $0.02
7
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...
Continue Reading
Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....
Continue Reading
A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...
Continue Reading
Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...
Continue Reading
Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...
Continue Reading
Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...
Continue Reading
Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...
Continue Reading
The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...
Continue Reading
A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...
Continue Reading
New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...
Continue Reading
Top 5 Most Recently Viewed Articles
Key Deadline for Metagenomi Investors As investors in Metagenomi, Inc. keep a close watch, an important deadline is approaching. The time to file a lead plaintiff motion in the class action lawsuit is set for November 25, 2024. This action is vital for those who purchased or acquired Metagenomi securities, specifically those linked to the company’s latest initial public...
Continue Reading
Structure Therapeutics Engages with Investors at Key Conferences Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company, is gearing up to participate in important investor conferences this September. The company is dedicated to developing innovative oral small molecule therapeutics aimed at treating metabolic and cardiopulmonary...
Continue Reading
OmaSp's Strong Financial Performance and Future Outlook OMA SAVINGS BANK PLC has recently released its financial statements for the year ending December 31, 2024, showing promising results and projections for continued growth. Known as OmaSp, the bank reported a noteworthy fourth quarter, aligning with the expectations set forth at the beginning of the year, and a solid...
Continue Reading
Reagan National Economic Forum Set to Inspire Economic Solutions The Ronald Reagan Presidential Foundation and Institute is gearing up for a transformative inaugural economic summit with leading figures from the business and economic policy landscapes to take place in late May 2025. About the Forum’s Objectives The Reagan National Economic Forum (RNEF) aims to provide a...
Continue Reading
Celebrating the Latino Business Community Prepare yourself for an unforgettable networking event dedicated to the Latino business community, brought to you by Latin Biz Today and Mercy University. The Spectrum of Success event promises a night filled with excitement, learning, and cultural experiences that will leave a lasting impression on everyone involved. A Night of...
Continue Reading